Andreas Hartkopf

32PUBLICATIONS
164CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersRehabilitation engineeringMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (32)

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Apr 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.

|Dec 30, 2025
Multi-Omics Tumor Immunogenicity Score Predicts Immunotherapy Outcome and Survival.

Axel Gschwind, Nadja Ballin, Alexander Ott

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

|Sep 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer.

Kerstin Pfister, Sophia Huesmann, Angelina Fink

|Jun 11, 2025
Correction: ENABLE-App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial.

Thomas M Deutsch, Léa L Volmer, Manuel Feisst

Pageof 6

Frequent Collaborators

14 joint publications

Tobias Engler

10 joint publications

Dominik Dannehl

8 joint publications

Sara Yvonne Brucker

8 joint publications

Andreas Schneeweiss